Dupont Capital Management’s AbbVie ABBV Stock Holding History

Dupont Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-56,052	Closed	-$12.2M	–	43
2026 Q1	$12.2M	Sell	56,052 -9,100	-14%	-$2.02M	1.39%	24
2025 Q4	$14.9M	Buy	65,152 +5,741	+10%	+$1.31M	1.68%	17
2025 Q3	$13.8M	Hold	59,411	–	–	1.42%	18
2025 Q2	$11M	Sell	59,411 -6,884	-10%	-$1.28M	1.19%	33
2025 Q1	$13.9M	Buy	66,295 +4,203	+7%	+$817K	1.54%	18
2024 Q4	$11M	Hold	62,092	–	–	1.03%	35
2024 Q3	$12.3M	Hold	62,092	–	–	1.02%	26
2024 Q2	$10.7M	Buy	+62,092	New	+$10.3M	0.93%	36
2023 Q3	–	Sell	-9,346	Closed	-$1.26M	–	226
2023 Q2	$1.26M	Sell	9,346 -1,756	-16%	-$258K	0.06%	142
2023 Q1	$1.77M	Sell	11,102 -4,072	-27%	-$623K	0.08%	116
2022 Q4	$2.45M	Sell	15,174 -11,840	-44%	-$1.82M	0.12%	119
2022 Q3	$3.63M	Sell	27,014 -22,481	-45%	-$3.23M	0.22%	78
2022 Q2	$7.58M	Buy	49,495 +12,037	+32%	+$1.84M	0.36%	38
2022 Q1	$6.07M	Buy	37,458 +10,916	+41%	+$1.59M	0.24%	63
2021 Q4	$3.59M	Sell	26,542 -16,692	-39%	-$1.97M	0.13%	149
2021 Q3	$4.66M	Sell	43,234 -11,722	-21%	-$1.34M	0.15%	131
2021 Q2	$6.19M	Sell	54,956 -1,613	-3%	-$182K	0.15%	110
2021 Q1	$6.12M	Sell	56,569 -7,289	-11%	-$780K	0.15%	111
2020 Q4	$6.84M	Sell	63,858 -3,048	-5%	-$293K	0.15%	119
2020 Q3	$5.86M	Sell	66,906 -5,624	-8%	-$529K	0.13%	135
2020 Q2	$7.12M	Buy	72,530 +15,434	+27%	+$1.36M	0.16%	118
2020 Q1	$4.35M	Buy	57,096 +8,017	+16%	+$683K	0.1%	146
2019 Q4	$4.34M	Sell	49,079 -1,849	-4%	-$154K	0.1%	176
2019 Q3	$3.86M	Buy	50,928 +3,681	+8%	+$252K	0.09%	200
2019 Q2	$3.44M	Sell	47,247 -5,900	-11%	-$464K	0.08%	246
2019 Q1	$4.28M	Sell	53,147 -36,166	-40%	-$2.96M	0.1%	198
2018 Q4	$8.23M	Sell	89,313 -20,452	-19%	-$1.8M	0.2%	92
2018 Q3	$10.4M	Sell	109,765 -9,982	-8%	-$947K	0.23%	78
2018 Q2	$11.1M	Sell	119,747 -16,490	-12%	-$1.61M	0.26%	70
2018 Q1	$12.9M	Buy	136,237 +44,828	+49%	+$4.92M	0.31%	60
2017 Q4	$8.84M	Buy	91,409 +661	+0.7%	+$62.3K	0.2%	96
2017 Q3	$8.06M	Sell	90,748 -24,743	-21%	-$1.88M	0.18%	105
2017 Q2	$8.37M	Buy	115,491 +19,227	+20%	+$1.29M	0.19%	106
2017 Q1	$6.27M	Sell	96,264 -2,426	-2%	-$153K	0.14%	139
2016 Q4	$6.18M	Sell	98,690 -17,612	-15%	-$1.08M	0.14%	140
2016 Q3	$7.33M	Buy	116,302 +15,978	+16%	+$1.03M	0.16%	129
2016 Q2	$6.21M	Sell	100,324 -23,563	-19%	-$1.44M	0.14%	140
2016 Q1	$7.08M	Buy	123,887 +32,052	+35%	+$1.79M	0.16%	135
2015 Q4	$5.44M	Sell	91,835 -16,663	-15%	-$960K	0.13%	164
2015 Q3	$5.9M	Hold	108,498	–	–	0.15%	157
2015 Q2	$7.29M	Buy	108,498 +67,938	+168%	+$4.44M	0.16%	135
2015 Q1	$2.37M	Buy	+40,560	New	+$2.45M	0.05%	339
2014 Q3	–	Sell	-26,100	Closed	-$1.47M	–	623
2014 Q2	$1.47M	Sell	26,100 -2,429	-9%	-$127K	0.02%	423
2014 Q1	$1.47M	Buy	28,529 +2,038	+8%	+$103K	0.02%	432
2013 Q4	$1.4M	Buy	26,491 +1,044	+4%	+$51.3K	0.02%	446
2013 Q3	$1.14M	Buy	+25,447	New	+$1.13M	0.02%	466

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dupont Capital Management's ABBV Position: Q2 2026 in Review

Dupont Capital Management sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 56,052 shares — an estimated $12.2M sold.

Dupont Capital Management first reported a position in ABBV in Q3 2013 and held it in 46 quarters. The position peaked at $14.9M in Q4 2025. 4,208 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Dupont Capital Management reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Dupont Capital Management sold 56,052 AbbVie shares in Q2 2026, an estimated $12.2M.
Dupont Capital Management first reported a position in AbbVie in Q3 2013 and held it in 46 quarters.
Dupont Capital Management's AbbVie position peaked at $14.9M in Q4 2025.
4,208 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Dupont Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.